- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.10. | C HEALTH GP (08225): VOLUNTARY ANNOUNCEMENT OF CHINA HEALTH GROUP INC. BUSINESS UPDATE | - | HKEx | ||
| 26.09. | C HEALTH GP (08225): INTERIM REPORT FOR THE SIX MONTHS ENDED 30 JUNE 2024 | - | HKEx | ||
| CHINA HEALTH GROUP INC Aktie jetzt für 0€ handeln | |||||
| 11.09. | C HEALTH GP (08225): RESIGNATION OF EXECUTIVE DIRECTOR AND APPOINTMENT OF EXECUTIVE DIRECTOR | - | HKEx | ||
| 11.09. | C HEALTH GP (08225): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 11.09. | C HEALTH GP (08225): COMPANY INFORMATION SHEET | - | HKEx | ||
| 29.08. | C HEALTH GP (08225): SUPPLEMENTARY ANNOUNCEMENT ON FINANCIAL ASSISTANCE | - | HKEx | ||
| 22.08. | C HEALTH GP (08225): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 | - | HKEx | ||
| 08.08. | C HEALTH GP (08225): NOTICE OF BOARD MEETING | - | HKEx |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TONIX PHARMACEUTICALS | 0,370 | -4,64 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia | Tonix received FDA's Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast... ► Artikel lesen | |
| HARROW | 33,660 | +0,63 % | Harrow Health Aktie: Stabile Aussichten? | Der Aktienkurs des Augenheilkunde-Spezialisten Harrow Health verzeichnete am 07. Dezember einen bemerkenswerten Anstieg von 5,08 Prozent auf 39,32 USD. Die Entwicklung steht im Kontrast zum negativen... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 1,760 | +15,03 % | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer | Industry veteran with extensive experience in key areas of focus
Interim-CFO Richard Narido to focus on HOPE Therapeutics acquisition opportunities
WILMINGTON, Del., Nov. 18, 2024... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 1,710 | -4,74 % | Reviva Pharmaceuticals: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial - - Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative... ► Artikel lesen | |
| ITERUM THERAPEUTICS | 1,920 | +10,34 % | Iterum Therapeutics PLC: Iterum Therapeutics Regains Full Nasdaq Compliance | DUBLIN and CHICAGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 36,980 | -0,72 % | PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen | DJ PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,495 | -0,57 % | Aquestive receives FDA Orphan Drug Exclusivity for Libervant | ||
| SKYE BIOSCIENCE | 2,510 | -1,95 % | Skye Bioscience, Inc.: Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor | SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health... ► Artikel lesen | |
| VYNE THERAPEUTICS | 2,925 | -1,52 % | VYNE Therapeutics Inc.: VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor | Promising results support VYN202's potential as a novel, once-daily oral treatment for a broad range of immune-mediated disordersConsistent with Phase 1a SAD results, VYN202 demonstrated a favorable... ► Artikel lesen | |
| PAINREFORM | 4,260 | -7,39 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen | |
| OMNIAB | 3,500 | -0,57 % | OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights | EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program... ► Artikel lesen | |
| JUPITER NEUROSCIENCES | 11,880 | +1,45 % | JUPITER NEUROSCIENCES, INC. - 10-Q, Quarterly Report | ||
| TRISALUS LIFE SCIENCES | 4,800 | +1,27 % | TriSalus Reports Q3 2024 Financial Results and Provides Business Update | DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver... ► Artikel lesen | |
| SUNSHINE BIOPHARMA | 3,120 | -3,11 % | Sunshine Biopharma, Inc.: Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus | FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic... ► Artikel lesen | |
| PMGC | 2,285 | -3,79 % | Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada | NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (Nasdaq: ELAB) (before and after the redomestication, the "Company" or "we") announced... ► Artikel lesen |
Das Unternehmen CHINA HEALTH GROUP INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,014 Euro und damit +16,67 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHINA HEALTH GROUP INC finden Sie auf Wallstreet Online.
